INS and cancer: Systemic inflammation, insulin‐dependent glucose handling and alterations in energy‐ and protein metabolism and pharmacokinetics have been proposed as pathophysiological mechanisms explaining the association between low skeletal muscle mass and poor clinical outcomes in older patients with cancer.19, 24, 26